What Investors Don't Understand About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is undergoing a significant transformation, with its Medical Devices segment now driving growth, particularly through the FreeStyle Libre glucose monitor. Despite a 28.8% stock decline this year, the company’s fundamentals remain strong, with a projected adjusted EPS of $5.38 to $5.58. The recent...